MYOMA
MCID: MYM001
MIFTS: 55

Myoma (MYOMA)

Categories: Cancer diseases, Muscle diseases, Reproductive diseases

Aliases & Classifications for Myoma

MalaCards integrated aliases for Myoma:

Name: Myoma 12 55 44 15 73
Neoplasms, Muscle Tissue 44 73
Muscle Benign Neoplasm 12 15
Myomatous Neoplasm 12 73
Benign Neoplasm of the Muscle 12
Muscle Tissue Neoplasm 12
Neoplasm of Muscle 12
Muscle Neoplasm 12
Myomatous Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2691 DOID:461
ICD10 33 D21
NCIt 50 C4882 C4063
SNOMED-CT 68 66357004 92237006

Summaries for Myoma

Disease Ontology : 12 A muscle benign neoplasm that is characterized as benign hyperplastic lesions of uterine smooth muscle cells.

MalaCards based summary : Myoma, also known as neoplasms, muscle tissue, is related to leiomyomatosis and adenomyosis, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Myoma is PGR (Progesterone Receptor), and among its related pathways/superpathways is Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics. The drugs Leuprolide and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and cervix, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 76 Myoma is a kind of mesenchymal... more...

Related Diseases for Myoma

Diseases related to Myoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)
# Related Disease Score Top Affiliating Genes
1 leiomyomatosis 30.4 ESR1 GNRH1 MED12 PGR
2 adenomyosis 30.3 CYP19A1 ESR1 GNRH1 HOXA10 PGR
3 endometrial stromal sarcoma 30.1 CYP19A1 ESR1 PGR
4 leiomyoma, uterine 30.1 ESR1 HMGA2 PGR
5 benign metastasizing leiomyoma 30.0 CYP19A1 PGR
6 endometriosis 30.0 CYP19A1 ESR1 GNRH1 HOXA10 PGR
7 leiomyoma 29.9 CYP19A1 ESR1 GNRH1 HMGA2 MED12 PGR
8 adhesions of uterus 29.9 ESR1 HOXA10
9 diffuse peritoneal leiomyomatosis 29.9 ESR1 MED12 PGR
10 pleomorphic lipoma 29.9 HMGA2 PGR
11 polycystic ovary syndrome 29.8 CYP19A1 GNRH1 LEP
12 endometrial cancer 29.6 CYP19A1 ESR1 GNRH1 HOXA10 PGR
13 endometrial adenocarcinoma 29.6 ESR1 HOXA10 PGR
14 breast fibroadenoma 29.5 CYP19A1 ESR1 HMGA2 MED12 PGR
15 skeletal muscle cancer 11.2
16 dartoic leiomyoma 11.2
17 carney complex variant 11.1
18 muscle cancer 11.0
19 mixed endometrial stromal and smooth muscle tumor 11.0
20 uterus leiomyosarcoma 10.8
21 thrombosis 10.3
22 vestibular gland benign neoplasm 10.3 ESR1 PGR
23 bartholin's gland adenoma 10.3 ESR1 PGR
24 vulvar syringoma 10.3 ESR1 PGR
25 glassy cell carcinoma of the cervix 10.3 ESR1 PGR
26 lung leiomyoma 10.3 ESR1 PGR
27 vulvar benign neoplasm 10.3 ESR1 PGR
28 trigonitis 10.3 ESR1 PGR
29 vulvar leiomyoma 10.3 ESR1 PGR
30 predominantly cortical thymoma 10.3 ESR1 PGR
31 breast medullary carcinoma 10.3 ESR1 PGR
32 breast scirrhous carcinoma 10.3 ESR1 PGR
33 bartholin's gland benign neoplasm 10.3 ESR1 PGR
34 oncocytic breast carcinoma 10.3 ESR1 PGR
35 bizarre leiomyoma 10.3 MED12 PGR
36 progesterone resistance 10.2 ESR1 PGR
37 endometrial squamous cell carcinoma 10.2 ESR1 PGR
38 cribriform carcinoma 10.2 ESR1 PGR
39 endometrial mucinous adenocarcinoma 10.2 ESR1 PGR
40 adenoid basal cell carcinoma 10.2 ESR1 PGR
41 breast adenoid cystic carcinoma 10.2 ESR1 PGR
42 apocrine adenocarcinoma 10.2 ESR1 PGR
43 deep angioma 10.2 ESR1 PGR
44 hypertensive encephalopathy 10.2 CYP19A1 EPO
45 synchronous bilateral breast carcinoma 10.2 ESR1 PGR
46 female reproductive endometrioid cancer 10.2 ESR1 PGR
47 cervical carcinosarcoma 10.2 ESR1 PGR
48 sarcoma 10.2
49 intramuscular hemangioma 10.2 ESR1 PGR
50 glycogen-rich clear cell breast carcinoma 10.2 ESR1 PGR

Graphical network of the top 20 diseases related to Myoma:



Diseases related to Myoma

Symptoms & Phenotypes for Myoma

UMLS symptoms related to Myoma:


muscle weakness, myoclonus, myalgia, torticollis, muscle rigidity, muscle cramp, muscle spasticity

MGI Mouse Phenotypes related to Myoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.19 CD3E CYP19A1 EPO ESR1 LEP MED12
2 homeostasis/metabolism MP:0005376 10.18 CYP19A1 EPO ESR1 GNRH1 HPSE2 LEP
3 endocrine/exocrine gland MP:0005379 10.16 CD3E CYP19A1 ESR1 GNRH1 HOXA10 LEP
4 hematopoietic system MP:0005397 10.15 CD3E CYP19A1 EPO ESR1 GNRH1 LEP
5 digestive/alimentary MP:0005381 10.13 CYP19A1 ESR1 GNRH1 HOXA10 HPSE2 LEP
6 immune system MP:0005387 10.11 CD3E CYP19A1 EPO ESR1 GNRH1 LEP
7 integument MP:0010771 10.09 CD3E CYP19A1 EPO ESR1 GNRH1 LEP
8 mortality/aging MP:0010768 10.07 CD3E EPO ESR1 HPSE2 LEP MED12
9 nervous system MP:0003631 9.91 CD3E CYP19A1 ESR1 GNRH1 HOXA10 LEP
10 limbs/digits/tail MP:0005371 9.88 EPO ESR1 HOXA10 LEP MED12 PGR
11 neoplasm MP:0002006 9.8 CD3E ESR1 GNRH1 LEP PGR XRCC4
12 renal/urinary system MP:0005367 9.7 CYP19A1 ESR1 GNRH1 HPSE2 LEP OXT
13 reproductive system MP:0005389 9.56 CYP19A1 ESR1 GNRH1 HOXA10 LEP OXT
14 skeleton MP:0005390 9.28 CYP19A1 EPO ESR1 GNRH1 HOXA10 LEP

Drugs & Therapeutics for Myoma

Drugs for Myoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4,Phase 3 53714-56-0 657181 3911
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 1,Phase 2 9004-61-9 53477741
3
Dimenhydrinate Approved Phase 4 523-87-5 441281
4
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
5
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Misoprostol Approved Phase 4,Phase 3 59122-46-2 5282381
8
Dinoprostone Approved Phase 4 363-24-6 5280360
9
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Not Applicable 1177-87-3
11
Nitrous oxide Approved, Vet_approved Phase 4,Not Applicable 10024-97-2 948
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
13
Everolimus Approved Phase 4 159351-69-6 6442177
14
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
15
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
16
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Not Applicable
18 Fertility Agents Phase 4
19 Carboxymethylcellulose Sodium Phase 4
20 Immunologic Factors Phase 4,Phase 1,Phase 2
21 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2
22 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
23 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2
24 Viscosupplements Phase 4,Phase 1,Phase 2
25 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
26 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
27 arginine Phase 4,Phase 3,Not Applicable
28 Natriuretic Agents Phase 4,Phase 3,Not Applicable
29 Coagulants Phase 4,Phase 3,Not Applicable
30 Vasoconstrictor Agents Phase 4,Phase 3,Not Applicable
31 Arginine Vasopressin Phase 4,Phase 3,Not Applicable
32 Hemostatics Phase 4,Phase 3,Not Applicable
33 Vasopressins Phase 4,Phase 3,Not Applicable
34 Estrogen Antagonists Phase 4
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Estrogens Phase 4
37 Estrogen Receptor Antagonists Phase 4
38 Steroid Synthesis Inhibitors Phase 4
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Aromatase Inhibitors Phase 4
42 Anesthetics Phase 4,Not Applicable
43 Anti-Arrhythmia Agents Phase 4,Not Applicable
44 Central Nervous System Depressants Phase 4,Not Applicable
45 Diuretics, Potassium Sparing Phase 4
46 Sodium Channel Blockers Phase 4
47 Anesthetics, Local Phase 4,Not Applicable
48 Anti-Ulcer Agents Phase 4,Phase 3
49 Antacids Phase 4,Phase 3
50 Oxytocics Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
2 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
3 Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
4 Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy Unknown status NCT01632202 Phase 4
5 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
6 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
7 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
8 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
9 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
10 Morphine vs. Oxycodone for Postoperative Pain Management Completed NCT00528177 Phase 4 Morphine and oxycodone
11 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Completed NCT00995878 Phase 4
12 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
13 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
14 Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions Terminated NCT01344486 Phase 4
15 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
16 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
17 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
18 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
19 PGL4001 Versus GnRH-agonist in Uterine Myomas Completed NCT00740831 Phase 3 PGL4001;leuprorelin
20 PGL4001 Versus Placebo in Uterine Myomas Completed NCT00755755 Phase 3 PGL4001 (ulipristal) and iron;PGL4001 matching placebo and iron;PGL4001 (ulipristal) and iron
21 Barbed Suture in Single-port Laparoscopic Myomectomy Completed NCT01984632 Phase 3
22 Vasopressin Versus Epinephrine in Myomectomy Completed NCT01861015 Phase 3 Epinephrine;Vasopressin
23 Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma Completed NCT01715597 Phase 3 ascorbic acid;Normal saline
24 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata Completed NCT01642472 Phase 3 Ulipristal Acetate - open label
25 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata Completed NCT01156857 Phase 3 PGL4001, placebo;PGL4001, progestin
26 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) Completed NCT01252069 Phase 3 PGL4001, placebo, drug free period;PGL4001, progestin, drug free period
27 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
28 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata Completed NCT01629563 Phase 3 PGL4001 5 mg;PGL4001 10 mg
29 Mifepristone for Treatment of Uterine Fibroids Completed NCT00712595 Phase 2, Phase 3 Mifepristone;Mifepristone
30 Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids Completed NCT00886873 Phase 2, Phase 3 Mifepristone
31 A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids Completed NCT02655237 Phase 3 TAK-385 40 mg;Leuprorelin 1.88 mg;Leuprorelin 3.75 mg
32 the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Recruiting NCT03483142 Phase 3 Misoprostol;Placebos
33 Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment Recruiting NCT02942537 Phase 2, Phase 3
34 Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy Terminated NCT01858454 Phase 3
35 Mifepristone to Treat Uterine Fibroids Terminated NCT01786226 Phase 2, Phase 3 Oral administration of mifepristone 2.5 mg daily for three months;Oral administration of mifepristone 5 mg daily for three months
36 Laparoscopic Myomectomy Using Barbed or Conventional Sutures Unknown status NCT02166411 Phase 2
37 Safety and Efficacy Study of a Hydrogel, Applied Following Removal of Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of Postoperative Adhesion Formation Completed NCT00562471 Phase 1, Phase 2
38 The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions Completed NCT02166554 Phase 1, Phase 2
39 Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids Completed NCT01452659 Phase 2 TAK-385;TAK-385;TAK-385;Placebo
40 Open Label Immunotherapy of Myoma Recruiting NCT03550703 Phase 2
41 The Impact of Treating Minor Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy in Unselected In Vitro Fertilization (IVF) Cases Terminated NCT00830401 Phase 2 Ofloxacinum/Doxycycline
42 Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery Completed NCT01745432 Phase 1
43 The Effect of Mifepristone on Uterine Fibroids and Breast Tissue Completed NCT00579475 Phase 1 Mifegyne;placebo
44 Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned Recruiting NCT03342859 Phase 1 Vilaprisan, BAY1002670;Ulipristal
45 A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet Withdrawn NCT03156127 Phase 1 BR-UPS 5 mg tablet, Inisia 5 mg tablet
46 Myoma Microvascularization Analysis Using Sonovue Before and After Uterine Artery Embolization Unknown status NCT00351494
47 Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal Unknown status NCT02737553 Not Applicable
48 Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy Unknown status NCT02377492 Not Applicable Vasopressins
49 Radio Frequency Ablation (RFA STUDY ) Unknown status NCT02631278 Not Applicable
50 Single or Triple Uterine Tourniquet at Myomectomy Unknown status NCT02392585 Not Applicable

Search NIH Clinical Center for Myoma

Cochrane evidence based reviews: myoma

Genetic Tests for Myoma

Anatomical Context for Myoma

MalaCards organs/tissues related to Myoma:

41
Uterus, Smooth Muscle, Cervix, Ovary, Kidney, Lung, B Cells

Publications for Myoma

Articles related to Myoma:

(show top 50) (show all 612)
# Title Authors Year
1
The uterine fibroid/myoma tumour: analysis of the global research architecture using density-equalizing mapping. ( 29198424 )
2018
2
Acute intestinal obstruction due to extrinsic compression by previa myoma and ectopic pregnancy: a case report. ( 29335010 )
2018
3
Transvaginal Natural Orifice Transluminal Endoscopic Surgery Myomectomy: A Novel Route for Uterine Myoma Removal. ( 29410143 )
2018
4
Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy. ( 29227004 )
2018
5
Modern Myoma Treatment in the Last 20 Years: A Review of the Literature. ( 29789793 )
2018
6
Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma. ( 29620641 )
2018
7
The expression of MA1llerian inhibiting substance/anti-MA1llerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )
2018
8
Dehiscence of a Low Transverse Cesarean Scar by a Submucous Myoma in a Nongravid Uterus. ( 29709694 )
2018
9
Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. ( 29408988 )
2018
10
Diagnosis and treatment of submucous myoma of the uterus with interventional ultrasound. ( 29616100 )
2018
11
Multimodal imaging for diagnosis and management of parasitic peritoneal myoma with myxoid degeneration after laparoscopic-assisted myomectomy with electric power morcellation. ( 29516586 )
2018
12
Morbidity, fertility and pregnancy outcomes after myoma enucleation by laparoscopy versus laparotomy. ( 29417281 )
2018
13
Incarceration of early gravid uterus with adenomyosis and myoma: report of two patients managed with uterine reduction. ( 30254999 )
2018
14
Multidisciplinary Approach in Large-sized Submucosal Myoma: Hysteroscopic Myomectomy after Uterine Artery Embolization. ( 29969685 )
2018
15
Regarding "Multidisciplinary Approach in Large-Sized Submucous Myoma: Hysteroscopic Myomectomy after Uterine Artery Embolization". ( 30165186 )
2018
16
Health Education Using Telephone and WeChat in Treatment of Symptomatic Uterine Myoma with High-Intensity Focused Ultrasound. ( 30185767 )
2018
17
Blood Serum Levels of Proinflammatory Cytokines (IL-1β, IL-6, TNFα, IL-8, IL-12p70, and IFNγ) in Patients with Uterine Myoma. ( 30225705 )
2018
18
Size, Type, and Location of Myoma as Predictors for Successful Laparoscopic Myomectomy: A Tertiary Government Hospital Experience. ( 30254939 )
2018
19
Recurrent Cerebral Infarction Due to Benign Uterine Myoma. ( 30366865 )
2018
20
Perioperative outcomes of myomectomy for extreme myoma burden: A comparison of surgical approaches. ( 30391510 )
2018
21
A case report of traditional Korean medicine treatments on uterine myoma with thyroid cancer. ( 30505680 )
2018
22
Dynamic thiol/disulphide homeostasis in patients with Uterine Myoma. ( 28697394 )
2017
23
Minimally Invasive Approaches to Myoma Management. ( 28734973 )
2017
24
Impact of pelvic magnetic resonance imaging findings in the indication of uterine artery embolization in the treatment of myoma. ( 28397200 )
2017
25
OUTCOME OF PREGNANCY WITH CLINICALLY VISIBLE/PALPABLE MYOMA AMONG WOMEN WHO UNDERGO CAESARIAN SECTION IN THREE TEACHING HOSPITALS, ADDIS ABABA, ETHIOPIA: A CROSS SECTIONAL STUDY. ( 29148636 )
2017
26
Psychiatric outcomes after hysterectomy in women with uterine myoma: a population-based retrospective cohort study. ( 28597115 )
2017
27
Pilot Study of the Mirabilis System Prototype for Rapid Noninvasive Uterine Myoma Treatment Using an Ultrasound-Guided Volumetric Shell Ablation Technique. ( 28109895 )
2017
28
Falsely Elevated Postvoid Residual Urine Volume in Uterine Myoma. ( 28503470 )
2017
29
Sacral Schwannoma Mimicking a Myoma Uterus. ( 28132872 )
2017
30
Pregnancy Outcomes After Direct Uterine Myoma Thermal Ablation: Review of the Literature. ( 28109894 )
2017
31
Unique Learning System for Uterine Artery Embolization for Symptomatic Myoma and Adenomyosis for Obstetrician-Gynecologists in Cooperation with Interventional Radiologists: Evaluation of UAE From the Point of View of Gynecologists Who Perform UAE. ( 28807810 )
2017
32
Myomectomies for massive hemoperitoneum from spontaneous bleeding of a uterine myoma. ( 28852453 )
2017
33
Increased risk of breast cancer in women with uterine myoma: a nationwide, population-based, case-control study. ( 28382798 )
2017
34
Urethrovaginal fistula following vaginal prolapse of a pedunculated uterine myoma: a case report. ( 29058627 )
2017
35
May-Thurner syndrome caused by a huge uterine myoma. ( 29296055 )
2017
36
Quality assessment of pelvic ultrasound for uterine myoma according to the CNGOF guidelines. ( 28643658 )
2017
37
Alcohol consumption and risk of uterine myoma: A systematic review and meta analysis. ( 29176884 )
2017
38
Novel management of a giant cervical myoma in a premenopausal patient. ( 28993358 )
2017
39
Incidence of Malignancy and Myoma Variants at Surgery for Presumed Benign Symptomatic Myomas. ( 28216458 )
2017
40
Myoma and myomectomy: Poor evidence concern in pregnancy. ( 28892210 )
2017
41
Rewriting the script: time to rethink the indications for myoma surgery. ( 28069179 )
2017
42
Myoma in Septic Necrobiosis at 10 Days Post-Partum. ( 29102219 )
2017
43
Laparoscopy or laparotomy as the way of entrance in myoma enucleation. ( 28819682 )
2017
44
Total laparoscopic hysterectomy for large uterine cervical myoma. ( 28515917 )
2017
45
A Lumbosacral Plexopathy Compressed by Huge Uterine Myoma. ( 29076826 )
2017
46
A case of secondary amenorrhea caused by uterine myoma successfully treated by a combined laparoscopic and hysteroscopic approach. ( 30254874 )
2017
47
Endometrial flushing αVβ3 integrin, glycodelin and PGF2α levels for evaluating endometrial receptivity in women with polycystic ovary syndrome, myoma uteri and endometrioma. ( 28454508 )
2017
48
Robotic-assisted single incision myomectomy in large myoma cases. ( 29746041 )
2017
49
Two unusual cases: vulvar lipoma - description of the largest case in literature. Developing myoma with the longest pedicle. ( 29953797 )
2017
50
Myoma-associated pain frequency and intensity: a retrospective evaluation of 1548 myoma patients. ( 26930041 )
2016

Variations for Myoma

Expression for Myoma

Search GEO for disease gene expression data for Myoma.

Pathways for Myoma

Pathways related to Myoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.23 CYP19A1 ESR1

GO Terms for Myoma

Biological processes related to Myoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.98 EPO ESR1 GNRH1 LEP OXT PGR
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.85 ESR1 HMGA2 HOXA10 MED12 PGR TLR9
3 regulation of signaling receptor activity GO:0010469 9.83 EPO GNRH1 LEP OXT
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.71 ESR1 MED12 PGR
5 response to estradiol GO:0032355 9.58 ESR1 LEP OXT
6 stem cell differentiation GO:0048863 9.55 ESR1 HMGA2
7 response to electrical stimulus GO:0051602 9.51 EPO OXT
8 female pregnancy GO:0007565 9.5 GNRH1 LEP OXT
9 eating behavior GO:0042755 9.49 LEP OXT
10 androgen metabolic process GO:0008209 9.48 CYP19A1 ESR1
11 intracellular steroid hormone receptor signaling pathway GO:0030518 9.46 ESR1 MED12
12 response to nutrient GO:0007584 9.43 CD3E EPO LEP
13 ovulation from ovarian follicle GO:0001542 9.16 LEP PGR
14 response to prostaglandin E GO:0034695 8.96 GNRH1 OXT
15 uterus development GO:0060065 8.8 CYP19A1 ESR1 HOXA10

Molecular functions related to Myoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.56 ESR1 HMGA2 HOXA10 PGR
2 proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001077 9.26 ESR1 HMGA2 HOXA10 PGR
3 steroid binding GO:0005496 9.16 ESR1 PGR
4 hormone activity GO:0005179 8.92 EPO GNRH1 LEP OXT

Sources for Myoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....